Evofem Biosciences, Inc. · OTC:EVFM

Evofem Biosciences — Investor Presentation (April 2021)

27 slides from Evofem Biosciences's investor presentation, Apr 7, 2021

1. Slide 1: Revolutionizing Women's Sexual and Reproductive Health

   1© 2021 Evofem Biosciences, Inc. For investor discussions only.For investor discussions only. Saundra Pelletier, CEO Revolutionizing Women’s Sexual and Reproductive Health NASDAQ: EVFM April 2021

2. Slide 2: Forward-Looking Statements

   2© 2021 Evofem Biosciences, Inc. For investor discussions only.For investor discussions only. Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases,

3. Slide 3: Evofem Biosciences 101

   3© 2021 Evofem Biosciences, Inc. For investor discussions only. Evofem Biosciences 101 Commercial-stage biopharmaceutical company First commercial product launched September 2020 o FDA-approved hormone-free, on-demand prescription contraceptive vaginal gel Phase 3 investigational candidate EVO100 fo

4. Slide 4: Large Market Opportunity

   4© 2021 Evofem Biosciences, Inc. For investor discussions only. 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015-2017. NCHS Data Brief. 2018; 327: 1-14. 2. Example market penetration in segment 3. Gross value of Phexxi user = $267.50 WAC x 7 annual refi

5. Slide 5: The Time is Right for Phexxi

   5© 2021 Evofem Biosciences, Inc. For investor discussions only. The Time is Right for Phexxi In the U.S., there are 23 million women at risk for pregnancy who are NOT using hormonal contraception1 5 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015-2017.

6. Slide 6: Driving the Phexxi Uptake Curve: Direct-To-Consumer Marketing

   6© 2021 Evofem Biosciences, Inc. For investor discussions only. Driving the Phexxi Uptake Curve: Direct-To-Consumer (DTC) Marketing 2021 Phexxi consumer marketing initiatives designed to reach women in a purposeful and targeted manner • High impact campaign across television, streaming and digital c

7. Slide 7: Get Phexxi – Rollout

   7© 2021 Evofem Biosciences, Inc. For investor discussions only.For investor discussions only. TELEVISION YOUTUBE SOCIAL MEDIA PHEXXI.COM DIGITAL MEDIA PRINT MATERIALS GET PHEXXI – ROLLOUT

8. Slide 8: Get Phexxi Ad

   8© 2021 Evofem Biosciences, Inc. For investor discussions only. FROM PDF, PLEASE ACCESS THE “GET PHEXXI” AD VIA HTTPS://WWW.YOUTUBE.COM/WATCH?V=6QSF5EGNKRW

9. Slide 9: Get Phexxi – Impact

   9© 2021 Evofem Biosciences, Inc. For investor discussions only. AWARENESS • Phexxi total brand awareness increased to 12.1% for March 2 • ~18X increase in weekly unpaid searches for “Phexxi” 1,3 • 171% increase in direct web traffic going right to Phexxi.com 1,3 DEMAND • 1.8X weekly increase in the

10. Slide 10: Phexxi Brand Awareness Growth Post-DTC

    10© 2021 Evofem Biosciences, Inc. For investor discussions only. Phexxi Brand Awareness Growth Post-DTC TV Online Social PHEXXI AWARENESS Awareness data based on surveys with patients conducted by Phoenix Brand Marketing Phexxi Total Brand Awareness: composite metric including Unaided Brand, Unaided

11. Slide 11: Accelerating Retail Demand

    11© 2021 Evofem Biosciences, Inc. For investor discussions only. - 1,000 2,000 3,000 4,000 5,000 6,000 7,000 Aug-20 Sep-20 Oct-20 Nov-20 Dec-20 Jan-21 Feb-21 Mar-21 852 Sales Units (wholesale to pharmacy) Dispensed Units (IQVIA) Accelerating Retail Demand “Get Phexxi” DTC Campaign Launch PHEXXI MONT

12. Slide 12: Monthly Prescription Growth

    12© 2021 Evofem Biosciences, Inc. For investor discussions only. Monthly Prescription Growth 375 967 1,100 1,378 1,542 2,147 4 46 133 231 236 292 0 500 1,000 1,500 2,000 2,500 3,000 Sept. 2020 Oct. 2020 Nov. 2020 Dec. 2020 Jan. 2021 Feb. 2021 PHEXXI PRESCRIPTIONS NRx Refills 1,233 379 1,013 1,609 So

13. Slide 13: HCPs Prescribing Phexxi

    13© 2021 Evofem Biosciences, Inc. For investor discussions only. 2 229 478 532 595 555 709 1 87 226 393 505 658 2 230 565 758 988 1,060 1,367 0 250 500 750 1,000 1,250 1,500 1,750 Aug. '20 Sep. '20 Oct. '20 Nov. '20 Dec. '20 Jan. '21 Feb. '21 HCPS PRESCRIBING PHEXXI New Prescribers Returning Over 3,

14. Slide 14: Reaching HCPs with "Best in Class" Sales Team

    14© 2021 Evofem Biosciences, Inc. For investor discussions only. Reaching HCPs with “Best in Class” Sales Team 70 Women’s Health sales reps and regional managers • Targeting ~3,500 accounts and the top 12K are the highest prescribing HCPs • Leveraging HCP segmentation tool to quickly refine target a

15. Slide 15: Favorable Data from Post-Concierge Surveys

    15© 2021 Evofem Biosciences, Inc. For investor discussions only. Favorable Data from Post-Concierge Surveys Hormone-free Doesn't impact cycle In the moment Ease of use Product Attributes Underlying Decision to Move Forward with Phexxi1 Source: 83Bar 11 November 2020 1. Question 9: “Why did you decid

16. Slide 16: Market Access

    16© 2021 Evofem Biosciences, Inc. For investor discussions only. Market Access Channel % of Lives Covered (3/31/21) Commercial 55.1% Medicaid 100.0% Notes: • Covered means patient has access to Phexxi, whether unrestricted or restricted access (i.e. prior authorizations or step therapy (trial of ano

17. Slide 17: Phexxi for Cancer Patients: NCODA Collaboration

    17© 2021 Evofem Biosciences, Inc. For investor discussions only. Phexxi for Cancer Patients: NCODA Collaboration • ~800,000 new cases of cancer reported annually among women1 • Many women with cancer are contraindicated to hormones • Collaboration to develop and share resources and educational infor

18. Slide 18: Pipeline: EVO100 for Prevention of Chlamydia and Gonorrhea in Women

    18© 2021 Evofem Biosciences, Inc. For investor discussions only. PIPELINE: EVO100 for Prevention of Chlamydia and Gonorrhea in Women EVO100 is investigational and safety and efficacy have not been established.

19. Slide 19: STI Prevention Market Opportunity

    19© 2021 Evofem Biosciences, Inc. For investor discussions only. STI Prevention Market Opportunity • 78M sexually active women potentially at risk for STIs (US)4 • Chlamydia and Gonorrhea infections are on the rise oUS chlamydia and gonorrhea infection rates increased for 5th consecutive year despit

20. Slide 20: EVOGUARD Phase 3 Trial Underway

    20© 2021 Evofem Biosciences, Inc. For investor discussions only. EVOGUARD Phase 3 Trial Underway • Phase 3, double-blind, placebo-controlled study to evaluate the efficacy of EVO100 in the prevention of urogenital Chlamydia trachomatis (CT) and Neisseria gonorrhea (GC) infection o16-week treatment p

21. Slide 21: EVO100: Expected Timeline to Approval

    21© 2021 Evofem Biosciences, Inc. For investor discussions only. EVO100: Expected Timeline to Approval 2021 2022 2023 Potential US Approval & Commercial Launch NDA submission2 Top-Line Results1 Initiate Pivotal Phase 3 Trial • FDA Fast Track designation for prevention of chlamydia in women • FDA QID

22. Slide 22: Financial Overview

    22© 2021 Evofem Biosciences, Inc. For investor discussions only. Financial Overview • Balance sheet at December 31, 2020 o$48.9M in unrestricted cash and equivalents o$22.2M in restricted cash from Adjuvant Capital • Raised $30M in March 2021 through underwritten equity offering • $4.5M in April fro

23. Slide 23: Gross-to-Net (GTN) Strategy

    23© 2021 Evofem Biosciences, Inc. For investor discussions only. Gross-to-Net (GTN) Strategy • Implementing strategies beginning April 2021 to improve margins oAdjusting components of existing co-pay assistance program oEstablishing traditional Phexxi sample program oEnhancing prior authorization as

24. Slide 24: IP Covering Phexxi Through 2033/2034

    24© 2021 Evofem Biosciences, Inc. For investor discussions only. IP Covering Phexxi Through 2033/2034 Evofem owns issued patents covering Phexxi through the following patent expiry dates: • March 15, 2033: U.S., Mexico, Australia, New Zealand, Singapore, India, Israel, Japan, Korea, Vietnam, Ukraine

25. Slide 25: Anticipated Milestones

    25© 2021 Evofem Biosciences, Inc. For investor discussions only. Anticipated Milestones üPublication of pivotal AMPREVENCE manuscript Q1 in American Journal of Obstetrics & Gynecology • Execute GTN improvement strategies Q2 • Announce Phexxi Celebrity Spokesperson Q3 • DTC campaign phase 2 launch Q3

26. Slide 26: Our Time is Now

    26© 2021 Evofem Biosciences, Inc. For investor discussions only. Our Time is Now • Paradigm shifting away from daily hormone dependency • Phexxi is the first and only hormone-free prescription contraception women control and use only when needed oSubstantial U.S. sales opportunity with even modest m

27. Slide 27: 27©

    27© 2021 Evofem Biosciences, Inc. For investor discussions only. © 2021 Evofem Biosciences, Inc.

Evofem Biosciences — Investor Presentation (April 2021) on 6ix